The Oncology Institute, Inc.
$3.52
▼
-0.64%
2026-04-21 09:52:00
theoncologyinstitute.com
NCM: TOI
Explore The Oncology Institute, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$349.89 M
Current Price
$3.52
52W High / Low
$4.88 / $1.8
Stock P/E
—
Book Value
$-0.16
Dividend Yield
—
ROCE
-38.51%
ROE
999.19%
Face Value
—
EPS
$-0.54
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Care Facilities
Employees
641
Beta
0.2
Debt / Equity
-6.6
Current Ratio
1.59
Quick Ratio
1.35
Forward P/E
-19.25
Price / Sales
0.61
Enterprise Value
$374.61 M
EV / EBITDA
-12.86
EV / Revenue
0.74
Rating
None
Target Price
$7
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | PACS Group, Inc. | $36 | 28.88 | $5.53 B | — | 6.76% | 22.96% | $43.08 / $7.5 | $6.04 |
| 2. | AMN Healthcare Services, Inc. | $20.46 | — | $790.91 M | — | 2.19% | -14.19% | $23.74 / $14.87 | $16.7 |
| 3. | agilon health, inc. | $28.3 | — | $499.01 M | — | -219.27% | -1.36% | $141 / $7.48 | $7.64 |
| 4. | Nutex Health Inc. | $109.28 | 11.86 | $761.5 M | 9.75% | 36.24% | 58.94% | $193.07 / $77.21 | $46.49 |
| 5. | Encompass Health Corporation | $103.27 | 18.68 | $10.28 B | 0.72% | 16.84% | 24.82% | $127.99 / $92.77 | $24.38 |
| 6. | Cryo-Cell International, Inc. | $3.56 | — | $27.71 M | 11.63% | 11.54% | 15.27% | $6.35 / $2.72 | $-2.31 |
| 7. | Chemed Corporation | $385.77 | 19.4 | $5.15 B | 0.62% | 27.27% | 25.28% | $593.8 / $365.2 | $71.44 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 141.96 M | 136.56 M | 119.8 M | 104.41 M | 100.27 M | — |
| Operating Profit | -6.91 M | -8.05 M | -11.21 M | -9.91 M | -11.93 M | — |
| Net Profit | -7.51 M | -16.5 M | -17.01 M | -19.59 M | -13.18 M | — |
| EPS in Rs | -0.08 | -0.17 | -0.17 | -0.2 | -0.13 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 502.73 M | 393.41 M | 324.24 M | 252.48 M |
| Operating Profit | -36.08 M | -60.12 M | -60.15 M | -72.01 M |
| Net Profit | -60.61 M | -64.66 M | -83.07 M | 0.15 M |
| EPS in Rs | -0.61 | -0.65 | -0.84 | 0 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 164.66 M | 172.72 M | 209.24 M | 261.67 M |
| Total Liabilities | 180.38 M | 169.13 M | 152.22 M | 138.49 M |
| Equity | -15.72 M | 3.59 M | 57.02 M | 123.17 M |
| Current Assets | 112.75 M | 112.42 M | 143.49 M | 130.42 M |
| Current Liabilities | 70.96 M | 52.22 M | 34.79 M | 29.72 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -24.59 M | -26.54 M | -36.31 M | -61.76 M |
| Investing CF | -3.07 M | 46.21 M | 62.64 M | -131.61 M |
| Financing CF | 11.56 M | -3.49 M | -6.85 M | 92.21 M |
| Free CF | -27.79 M | -30.33 M | -40.88 M | -67.28 M |
| Capex | -3.2 M | -3.79 M | -4.57 M | -5.53 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 21.33% | 28.42% | — | — |
| Earnings Growth % | 22.16% | -54750% | — | — |
| Profit Margin % | -16.44% | -25.62% | 0.06% | — |
| Operating Margin % | -15.28% | -18.55% | -28.52% | — |
| Gross Margin % | 13.73% | 18.37% | 20.63% | — |
| EBITDA Margin % | -12.93% | -21.73% | 3.33% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.